| Pooled treatment outcomes# | MDR-TB only | MDR-TB +INJr | MDR-TB +FQr | XDR-TB | Total |
| Subjects | 4763 | 1130 | 426 | 405 | 6724 |
| Treatment success | 64 (57–72) | 56 (45–66) | 48 (36–60) | 40 (27–53) | 62 (54–69) |
| Treatment failure or relapse | 4 (2–6) | 12 (9–15) | 18 (14–21) | 22 (15–28) | 7 (4–9) |
| Died | 8 (5–11) | 8 (3–14) | 11 (3–19) | 15 (8–23) | 9 (5–12) |
| Defaulted | 18 (12–24) | 16 (7–24) | 12 (1–23) | 16 (8–24) | 17 (11–22) |
Data are presented as n or % (95% CI). MDR-TB: multidrug-resistant TB (resistance to at least isoniazid and rifampicin); MDR-TB only: as MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested); MDR-TB+INJr: MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones; MDR-TB+FQr: MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested); XDR-TB: extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)). #: from study level meta-analysis; column percentages do not total 100%. See the Methods section and [17] for treatment outcome definitions.